RANI Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	477 354
Średni wolumen	137 011
Kapitalizacja rynkowa	360.46M
EPS	$0 ( 2024-03-27 )
Następna data zysków	( $-0.230 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-5.38
ATR14	$0.0440 (0.62%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-21	Mckinley Kate	Buy	323 500	Stock Option (Right to Buy)
2024-03-21	Hashim Mir	Buy	323 500	Stock Option (Right to Buy)
2024-03-21	Groen Eric	Buy	323 500	Stock Option (Right to Buy)
2024-03-21	Imran Talat	Buy	1 085 000	Stock Option (Right to Buy)
2024-03-21	Sanford Svai S	Buy	323 500	Stock Option (Right to Buy)

INSIDER POWER
19.25
Last 99 transactions
Buy: 12 150 348 \| Sell: 8 157 844

Wolumen Korelacja

Długi: 0.02 (neutral)

Krótki: 0.43 (neutral)

Signal:(53.823) Neutral

Rani Therapeutics Korelacja

10 Najbardziej pozytywne korelacje
CATB	0.948
NYMX	0.94
ABIO	0.915
CADL	0.915
SGRP	0.912
AURC	0.911
MDIA	0.909
GRIN	0.908
CSTE	0.902
GALT	0.898

10 Najbardziej negatywne korelacje
YVR	-0.925
ARIZ	-0.921
ARVL	-0.904
ENNVU	-0.901
DUNE	-0.888
ACOR	-0.887
MBIO	-0.885
CASA	-0.883
CIIG	-0.875
ENVI	-0.872

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Rani Therapeutics Korelacja - Waluta/Towar

0.52
( weak )

0.58
( weak )

0.00
( neutral )

0.14
( neutral )

-0.06
( neutral )

Rani Therapeutics Finanse

Annual	2023
Przychody:	$0
Zysk brutto:	$-822 000 (0.00 %)
EPS:	$-1.330

FY	2023
Przychody:	$0
Zysk brutto:	$-822 000 (0.00 %)
EPS:	$-1.330

FY	2022
Przychody:	$0
Zysk brutto:	$-1.31M (0.00 %)
EPS:	$-2.66

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-0.445

Financial Reports:

No articles found.

Rani Therapeutics

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.

Aktualne aktualizacje dla Rani Therapeutics [RANI]

Upcoming Earnings Alert